LXRX

#2654
Lexicon Pharmaceuticals, Inc.
1.75 USD
+2.34%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
1.75
1.75
年范围
0.48
1.84
日变化
+2.34%
每月变动
+2.94%
6个月变化
+17.45%
年变化
+230.19%
前一天收盘价
1.71
开盘价
1.75
买价
卖价
最低价
1.75
High
1.75
交易量
28
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 741.44 M
  • Employee 81
  • Founded 1995
  • CEO Lonnel Coats
  • Website www.lexpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000BQ85G2
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-8.21
市销率
8.38

Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.

新闻